The assay reliably detected EGFR alterations over a VAF range from 1.7 to 89.2%, and the failure rate of samples with low tumor cell content (20–30%) was not higher than for samples with higher tumor cell content (≥40%). The gene discussed is EGFR; the disease is neoplasm.